Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Sizzling DOAC Market - 3: Dosage and Administration Vary by Product for PE/DVT Treatment
The four direct oral anticoagulants (DOACs) are difficult to clearly distinguish from each other in terms of safety and efficacy. Each company has adopted different marketing policies for its product. Let’s look at the indication of pulmonary thromboembolism/deep vein thromboembolism…
To read the full story
Related Article
- Sizzling DOAC Market - 4: Companies Aim to Differentiate Their Products through Quality of Information
August 29, 2016
- Sizzling DOAC Market - 2: Makers Accumulating Data from Actual Clinical Settings to Support Proper Use
August 25, 2016
- Sizzling DOAC Market - 1: Japan Sales Reaching 140 Billion Yen on 4-Way Fight
August 24, 2016
BUSINESS
- Drug Makers, Wholesalers Rush to Gauge Kumamoto Quake Impact
July 29, 2026
- Pfizer Brings Eisai into Nurtec Promotion in Japan
July 28, 2026
- Celltrion, Nippon Kayaku Broaden Alliance in Biopharma Biz
July 28, 2026
- Ishin Eyes Domestic Production of Allostem by August 2028
July 28, 2026
- Enhertu Combo Bags EU Panel Nod in 1st-Line HER2 Breast Cancer
July 28, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…